EU/3/10/749:

Recombinant human anti-interferon gamma monoclonal antibody (emapalumab)

Table of contents

Overview

On 9 June 2010, orphan designation (EU/3/10/749) was granted by the European Commission to NovImmune B.V., the Netherlands, for recombinant human anti-interferon gamma monoclonal antibody for the treatment of haemophagocytic lymphohistiocytosis.

This medicine is now known as emapalumab.

The sponsorship was transferred to Swedish Orphan Biovitrum AB (publ), Sweden, in June 2019.

Key facts

Active substance
Recombinant human anti-interferon gamma monoclonal antibody (emapalumab)
Intented use
Treatment of haemophagocytic lymphohistiocytosis
Date of designation
09/06/2010
Orphan designation status
Positive
EU designation number
EU/3/10/749

Sponsor's contact details

Swedish Orphan Biovitrum AB (publ)
SE 112 76 Stockholm
Sweden
E-mail: info@sobi.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

Related content

How useful was this page?

Add your rating